CompaniesBioInvent International

BioInvent International

active

Lund, Sweden

Founded 1997

Website

About

Antibody Drugs

Areas of Focus

Categories

Biologics & BiopharmaceuticalAntibody

Clinical Trials (54)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

28,572

By Phase

PHASE1/PHASE2: 15PHASE2: 17NA: 5PHASE1: 7PHASE4: 1PHASE3: 5

By Status

COMPLETED: 27RECRUITING: 8TERMINATED: 8ACTIVE_NOT_RECRUITING: 3WITHDRAWN: 3UNKNOWN: 3NOT_YET_RECRUITING: 1SUSPENDED: 1

Clinical Trials Pipeline54 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

Today

NCT00091676

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2000

Completion: Dec 31, 2012

NCT00091676

NCT00328263

Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2006

Completion: Oct 31, 2007

NCT00612196

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Phase: Phase 1

Role: Collaborator

Start: Mar 31, 2007

Completion: Dec 31, 2007

NCT00612417

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

Phase: Phase 1

Role: Collaborator

Start: Jan 31, 2008

Completion: Jun 30, 2008

NCT00618579

Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin

Phase: Phase 1

Role: Collaborator

Start: Feb 29, 2008

Completion: Aug 31, 2008

NCT00737412

Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2008

Completion: Jan 31, 2010

NCT00702494

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2008

Completion: Sep 30, 2009

NCT00958308

Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 31, 2008

Completion: Apr 30, 2009

NCT00793234

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

Phase: Phase 2

Role: Collaborator

Start: Dec 31, 2008

Completion: Mar 31, 2010

NCT01025206

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2009

Completion: Feb 28, 2013

NCT00941356

Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

Phase: Phase 2

Role: Lead Sponsor

Start: Jan 31, 2010

Completion: Jul 31, 2016

NCT00941356

NCT00926068

Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers

Phase: Phase 2

Role: Collaborator

Start: Feb 28, 2010

Completion: Not specified

NCT00926068

NCT01258907

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Phase: Phase 2

Role: Collaborator

Start: Mar 31, 2010

Completion: Not specified

NCT01258907

NCT01202630

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2010

Completion: Jan 31, 2016

NCT01202630

NCT01344954

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Phase: Phase 2

Role: Collaborator

Start: Apr 30, 2011

Completion: May 31, 2012

NCT01486823

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2011

Completion: Jul 31, 2012

NCT01545037

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 31, 2012

Completion: Jan 31, 2015

NCT01838369

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2013

Completion: Dec 31, 2014

NCT02091596

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

Phase: Phase 2

Role: Collaborator

Start: Oct 31, 2013

Completion: Sep 30, 2014

NCT02119754

Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers

Phase: Phase 2

Role: Collaborator

Start: Oct 31, 2013

Completion: Sep 30, 2014

NCT01972932

Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea

Phase: Phase 4

Role: Lead Sponsor

Start: Nov 30, 2013

Completion: Aug 31, 2017

NCT04472455

Mobile High-Resolution Microendoscopy (mHRME) for the Detection of Cervical Dysplasia in El Salvador

Phase: N/A

Role: Collaborator

Start: Sep 30, 2015

Completion: Apr 2, 2019

NCT02814448

An Innovative Treatment for Cervical Pre Cancer

Phase: N/A

Role: Collaborator

Start: Feb 29, 2016

Completion: Dec 31, 2016

NCT02756728

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Phase: Phase 1/2

Role: Lead Sponsor

Start: May 31, 2016

Completion: Dec 31, 2016

NCT02697591

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jun 20, 2016

Completion: Dec 16, 2019

NCT02626988

The Role of Agricultural Biodiversity in The Diet: a Vietnamese Study

Phase: N/A

Role: Lead Sponsor

Start: Aug 5, 2016

Completion: Dec 11, 2017

NCT02933320

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

Phase: Phase 1/2

Role: Collaborator

Start: Oct 27, 2016

Completion: Mar 19, 2020

NCT02923349

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Phase: Phase 1/2

Role: Lead Sponsor

Start: Oct 31, 2016

Completion: Mar 26, 2019

NCT03126110

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Phase: Phase 1/2

Role: Lead Sponsor

Start: Apr 25, 2017

Completion: Nov 9, 2021

NCT03084081

An Innovative Treatment for Cervical Precancer (UH3)

Phase: N/A

Role: Collaborator

Start: Aug 1, 2017

Completion: Aug 15, 2024

NCT03084081

NCT03239366

A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 6, 2017

Completion: Jun 30, 2019

NCT03241173

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Phase: Phase 1/2

Role: Lead Sponsor

Start: Oct 9, 2017

Completion: Sep 17, 2019

NCT03277352

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Phase: Phase 1/2

Role: Lead Sponsor

Start: Nov 21, 2017

Completion: Jul 1, 2020

NCT03571568

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Phase: Phase 1/2

Role: Lead Sponsor

Start: May 16, 2018

Completion: Sep 30, 2026

NCT03571568

NCT03538028

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 18, 2018

Completion: Oct 7, 2020

NCT03807479

Study in Patients With Chronic Leukemia

Phase: Phase 2

Role: Collaborator

Start: Dec 11, 2018

Completion: Aug 31, 2023

NCT03515785

"A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - POSEIDON"

Phase: N/A

Role: Lead Sponsor

Start: Dec 31, 2018

Completion: Mar 31, 2021

NCT03934372

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jan 29, 2020

Completion: Jan 30, 2026

NCT03934372

NCT04231981

Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

Phase: Phase 2

Role: Collaborator

Start: Apr 28, 2020

Completion: Aug 26, 2022

NCT04219254

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jun 29, 2020

Completion: Nov 30, 2027

NCT04219254

NCT04294277

Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery

Phase: Phase 2

Role: Collaborator

Start: Jul 13, 2020

Completion: Nov 15, 2022

NCT03429582

Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device

Phase: N/A

Role: Collaborator

Start: Oct 30, 2020

Completion: Jul 1, 2025

NCT04752826

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jan 25, 2021

Completion: Jan 15, 2028

NCT04752826

NCT04725331

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Phase: Phase 1/2

Role: Collaborator

Start: Feb 25, 2021

Completion: Apr 30, 2025

NCT05555251

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jul 28, 2022

Completion: Feb 7, 2024

NCT05565794

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Phase: Phase 2

Role: Collaborator

Start: Nov 11, 2022

Completion: Mar 27, 2025

NCT05287113

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 14, 2022

Completion: Jul 10, 2026

NCT04968106

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Phase: Phase 2

Role: Collaborator

Start: Dec 7, 2022

Completion: Oct 31, 2027

NCT05431699

Single Visit Clinical Validation of ScreenFire, a Low-cost HPV Test